Report Description Table of Contents Genetic Diagnosis and Syndrome-Specific Therapies Advance Lifelong Dravet Syndrome Management The Global Dravet Syndrome Treatment Market was valued at USD 470 million in 2025 and is projected to reach USD 937 million by 2032, expanding at a CAGR of 10.25% during 2026–2032, according to Strategic Market Research. Dravet syndrome (DS) is a rare, severe genetic epilepsy disorder that typically begins during infancy and requires lifelong disease management. The treatment landscape focuses on reducing seizure frequency, preventing life-threatening complications, and improving patient quality of life through a combination of maintenance antiseizure medications, rescue therapies, ketogenic diet, seizure-trigger management, rehabilitation, and neuromodulation for selected refractory cases. More than 80% of diagnosed patients carry SCN1A gene variants, making genetic testing an increasingly important tool for diagnosis, treatment selection, and clinical-trial enrollment. Dravet syndrome affects approximately 1 in 40,000 individuals globally, with regional prevalence estimates ranging from 1.5–6.5 cases per 100,000 people. In the United States, population-based studies estimate incidence at approximately 1 in 15,700 live births, while around 10,000 individuals are estimated to live with the condition. Despite advances in diagnosis and treatment, DS remains associated with significant mortality risk, with 15–20% of patients experiencing premature death, primarily due to Sudden Unexpected Death in Epilepsy (SUDEP), status epilepticus, severe infections, and accidental events. Improved management strategies now allow approximately 80–85% of patients to survive into adulthood. The FDA-approved treatment landscape is centered on targeted therapies that address severe seizure burden. Epidiolex (cannabidiol), an oral CBD-based therapy, is approved for patients aged 1 year and older and helps reduce seizure frequency. Fintepla (fenfluramine) is approved as an adjunctive therapy for patients aged 2 years and older, demonstrating significant reductions in convulsive seizures. Diacomit (stiripentol) is an anticonvulsant used in combination with clobazam to improve seizure control. Together, these therapies represent the foundation of modern Dravet syndrome management. Overall Conclusion: Market is evolving from symptomatic seizure control toward precision-based disease management, driven by genetic diagnosis, targeted therapies, and ongoing innovation in rare epilepsy care. Rising awareness, improved genetic testing, and the development of novel treatment approaches are expected to support continued market growth while addressing the significant unmet need associated with this lifelong neurological disorder. Key Dravet Syndrome Treatment Market Takeaways by Segment By Treatment Type: Antiepileptic Drugs: The leading segment held 38% of the market and was valued at USD 178.6 million in 2025, supported by the continued use of valproate, clobazam, and other maintenance antiseizure medicines. Cannabidiol-Based Therapies: This segment accounted for 20% of the market and USD 94 million in 2025, with growth supported by regulated pharmaceutical-grade cannabidiol and established reimbursement pathways. Fenfluramine-Based Therapies: The segment represented 18% of the market and USD 84.6 million in 2025, reflecting clinically meaningful convulsive-seizure reductions and specialist adoption. Stiripentol Therapy: Stiripentol held a 12% share and reached USD 56.4 million in 2025 through its syndrome-specific add-on position with clobazam. Gene-Targeted Therapies: The fastest-growing category accounted for 7% and USD 32.9 million in 2025, reflecting clinical-development, licensing, and research activity surrounding SCN1A-directed therapies rather than approved product sales. Adjunctive Therapies: This category captured 5% and USD 23.5 million in 2025 through rescue medicines, ketogenic nutrition, neuromodulation, and supportive interventions. By Therapy Approach: Pharmacological Treatment: The dominant approach held 88% of the market and generated USD 413.6 million in 2025 because most patients require long-term multidrug treatment. Non-Pharmacological Treatment: This segment represented 12% and USD 56.4 million in 2025 through ketogenic dietary programs, vagus nerve stimulation, trigger management, and supportive care. By Distribution Channel: Hospital Pharmacies: The leading channel held 52% of the market and reached USD 244.4 million in 2025 because specialty treatment frequently begins through pediatric neurology and comprehensive epilepsy centers. Retail Pharmacies: Retail pharmacies represented 30% and USD 141 million in 2025, primarily serving established maintenance and rescue medicines used in outpatient care. Online Pharmacies: This channel accounted for 18% and USD 84.6 million in 2025, supported by coordinated specialty dispensing and direct-to-patient medicine delivery. By End User: Hospitals & Specialty Clinics: The dominant end-user category held 62% of the market and generated USD 291.4 million in 2025 through specialist diagnosis, treatment selection, monitoring, and emergency care. Diagnostic Laboratories: Laboratories accounted for 10% and USD 47 million in 2025 as genetic testing increasingly influences clinical decisions and trial enrollment. Research Institutes: This segment held 8% and USD 37.6 million in 2025 through natural-history research, patient registries, biomarker studies, and genetic-therapy development. Pharmaceutical Companies: Pharmaceutical and biotechnology companies represented 20% and USD 94 million in 2025 through rare-epilepsy portfolios and SCN1A-directed development programs. By Geography: North America: The leading regional market held 45% and was valued at USD 211.5 million in 2025, supported by genetic testing, approved branded medicines, specialty pharmacies, and active genetic-therapy trials. Europe: Europe accounted for 28% and USD 131.6 million in 2025, supported by orphan-medicine frameworks, national reimbursement systems, epilepsy centers, and patient registries. Asia Pacific: The fastest-growing region held 18% and USD 84.6 million in 2025 as diagnosis and access to rare-epilepsy treatment improve across major healthcare systems. Latin America: The region represented 6% and USD 28.2 million in 2025, with market development concentrated in major urban neurology centers. Middle East & Africa: This region accounted for 3% and USD 14.1 million in 2025, reflecting uneven genetic-testing availability and limited access to syndrome-specific medicines. Antiepileptic Medicines Lead While SCN1A-Targeted Therapies Accelerate Leading Segment — Antiepileptic Drugs: Antiepileptic drugs led the market with a 38% share and a value of USD 178.6 million in 2025, expanding at a CAGR of 8.2%. Valproate and clobazam remain foundational treatments because they provide broad seizure control and are commonly used before syndrome-specific therapies are introduced. These medicines are also frequently retained as background therapy when cannabidiol, fenfluramine, or stiripentol is added, supporting continued prescription volume despite their established market position. Fastest-Growing Segment — Gene-Targeted Therapies: Gene-targeted therapies accounted for a 7% share and USD 32.9 million in 2025 and are projected to grow at the fastest CAGR of 25.0%. Segment growth reflects research, licensing, clinical-trial, and development activity involving therapies designed to address SCN1A-related disease biology. Important candidates include Stoke Therapeutics and Biogen’s Phase III antisense oligonucleotide zorevunersen and Encoded Therapeutics’ Phase I/II gene-regulation therapy ETX101, both of which remain investigational rather than commercially approved. Long-Term Pharmacotherapy Dominates as Multidisciplinary Care Expands Leading Segment — Pharmacological Treatment: Pharmacological treatment dominated with an 88% market share and USD 413.6 million in 2025, growing at a CAGR of 9.5%. Most patients require lifelong multidrug treatment involving maintenance antiseizure medicines, syndrome-specific add-on therapies, and rescue medications for prolonged seizure events. Recurring daily administration and the integration of branded products such as Epidiolex, Fintepla, and Diacomit sustain the segment’s commercial leadership. Fastest-Growing Segment — Non-Pharmacological Treatment: Non-pharmacological treatment held a 12% share and was valued at USD 56.4 million in 2025, with a projected CAGR of 15.0%. Ketogenic dietary therapy and vagus nerve stimulation are used for selected patients whose seizures remain inadequately controlled despite multidrug pharmacotherapy. Wider multidisciplinary management—including nutritional supervision, rehabilitation, trigger control, and supportive care—is expanding this segment’s role alongside medication rather than as a replacement for it. Hospital Pharmacies Anchor Treatment Initiation While Digital Fulfilment Improves Continuity Leading Segment — Hospital Pharmacies: Hospital pharmacies led with a 52% market share and USD 244.4 million in 2025, advancing at a CAGR of 9.2%. Dravet syndrome treatment is frequently initiated through comprehensive epilepsy centers and pediatric neurology departments, where specialists confirm diagnosis and select appropriate drug combinations. Hospital-connected pharmacies also support prior authorization, controlled dispensing, and hepatic or cardiac monitoring required for certain syndrome-specific treatments. Fastest-Growing Segment — Online Pharmacies: Online pharmacies represented an 18% share and USD 84.6 million in 2025 and are projected to expand at a CAGR of 14.5%. Their growth is supported by coordinated refill management, specialty-medicine fulfillment, adherence services, and direct delivery to families managing complex lifelong therapy. Digital pharmacy models are particularly relevant when patients live far from specialist epilepsy centers, although product availability continues to depend on prescription and specialty-distribution requirements. Specialist Care Leads While Research Infrastructure Supports Disease Modification Leading Segment — Hospitals & Specialty Clinics: Hospitals and specialty clinics dominated with a 62% market share and USD 291.4 million in 2025, growing at a CAGR of 10.0%. These facilities manage SCN1A genetic confirmation, multidrug selection, adverse-event monitoring, ketogenic dietary programs, and emergency treatment for prolonged seizures. Their clinical infrastructure also makes them the principal setting for patient-registry participation and referral into trials evaluating disease-modifying therapies. Fastest-Growing Segment — Research Institutes: Research institutes held an 8% share and USD 37.6 million in 2025 and are projected to register the fastest CAGR of 16.0%. Growth is connected to natural-history studies, patient registries, SCN1A-focused research, biomarker development, and clinical trials of antisense and gene-regulation therapies. Research centers are also helping expand clinical endpoints beyond seizure frequency to include communication, behavior, mobility, cognition, and adaptive functioning. North America Leads Commercial Access as Asia Pacific Expands Rare-Epilepsy Diagnosis Leading Segment — North America: North America led with a 45% share and a market value of USD 211.5 million in 2025, expanding at a CAGR of 9.8%. The region benefits from broader access to epilepsy genetic panels, comprehensive pediatric epilepsy centers, specialty pharmacies, and FDA-approved Dravet therapies such as Epidiolex, Fintepla, and Diacomit. Active clinical programs involving zorevunersen and ETX101 further strengthen North America’s position in the transition toward SCN1A-directed treatment. Fastest-Growing Segment — Asia Pacific: Asia Pacific accounted for an 18% share and USD 84.6 million in 2025 and is projected to grow at the fastest regional CAGR of 12.8%. Molecular diagnosis and rare-epilepsy services are improving across Japan, Australia, South Korea, China, and other major healthcare systems. Additional product registrations, specialist training, and better recognition of patients previously classified under broader drug-resistant epilepsy diagnoses are expected to expand the region’s treated population. Leading Top Three Companies in the Dravet Syndrome Treatment Market UCB UCB is a leading company in the Dravet Syndrome Treatment Market through Fintepla, an FDA-approved fenfluramine oral solution for seizures associated with Dravet syndrome in patients aged two years and older. Fintepla is differentiated by substantial convulsive-seizure reductions among responders and occupies an important position for patients whose seizures remain inadequately controlled by earlier therapies. UCB supports the product through an established rare-epilepsy commercial network, specialist-physician engagement, patient-access services, and international commercialization. Cardiac monitoring requirements add complexity to treatment initiation but also create a closely supervised care pathway that strengthens UCB’s position within specialty epilepsy centers. Jazz Pharmaceuticals Jazz Pharmaceuticals is a leading participant through Epidiolex in the United States and Epidyolex in international markets. This pharmaceutical-grade cannabidiol formulation is approved for seizures associated with Dravet syndrome and other severe epilepsy conditions, providing Jazz with a broad rare-epilepsy prescriber base and established reimbursement infrastructure. The product benefits from randomized clinical evidence, standardized dosing, specialty-pharmacy distribution, and availability across multiple countries. Epidiolex/Epidyolex generated approximately USD 1.06 billion in 2025 across all approved indications—not Dravet syndrome alone—demonstrating the commercial scale and geographic reach of Jazz’s rare-epilepsy franchise. Biocodex Biocodex is a leading Dravet-focused company through Diacomit, or stiripentol, an FDA-approved therapy for seizures associated with Dravet syndrome in eligible patients taking clobazam. Its syndrome-specific indication, established pediatric use, and long clinical history give Biocodex a specialized position within combination-treatment protocols. Diacomit remains commercially relevant for patients requiring escalation beyond first-line valproate and clobazam. Although newer treatments have expanded physician choice, Biocodex retains leadership through focused disease expertise, international product availability, and stiripentol’s recognized place in Dravet treatment recommendations. Companies Not Currently Classified as Market Leaders Stoke Therapeutics and Biogen are important pipeline participants through Phase III zorevunersen, while Encoded Therapeutics is developing Phase I/II ETX101; however, they are not currently leading commercial companies because their Dravet-targeted genetic therapies remain investigational and have not received marketing approval. Future Commercial Outlook: Expanding the Opportunity Beyond Symptom Control Toward Disease-Modifying Therapies The future commercial opportunity in the Dravet Syndrome Treatment Market will increasingly shift toward therapies capable of modifying the underlying SCN1A-related disease mechanism rather than only managing seizure symptoms. While currently approved medicines have established a strong treatment foundation, significant whitespace remains in reducing developmental impairment, improving neurological outcomes, preventing SUDEP-related mortality, and addressing patients who continue to experience uncontrolled seizures despite optimized therapy. This unmet need creates a high-value opportunity for next-generation precision medicines, particularly antisense oligonucleotides, gene-regulation therapies, and other genomic approaches designed specifically for Dravet syndrome biology. The transition toward earlier genetic diagnosis represents another major commercial opportunity. As SCN1A testing becomes more integrated into pediatric epilepsy evaluation, more patients are expected to be identified earlier in the disease course and connected with syndrome-specific therapies. Earlier diagnosis may expand the addressable treatment population by reducing delayed recognition of Dravet syndrome and enabling earlier intervention before prolonged seizure exposure contributes to irreversible developmental complications. Companies that combine targeted therapeutics with companion diagnostics, patient identification programs, and specialist-center networks are likely to gain strategic advantages. Future market expansion will also depend on improving access beyond established North American and European markets. Asia Pacific and other emerging regions represent underpenetrated opportunities due to improving rare-disease awareness, expanding genetic testing infrastructure, and increasing investment in specialty neurology care. Commercial success in these markets will depend on reimbursement strategies, physician education, regional clinical partnerships, and localized access models for high-cost orphan therapies. The competitive landscape is expected to evolve from a small group of commercial epilepsy specialists into a broader rare-neurology ecosystem involving pharmaceutical companies, biotechnology firms, genetic-medicine developers, diagnostic providers, and research institutions. Pipeline success in SCN1A-directed therapies could redefine treatment value by shifting pricing discussions from lifelong seizure management toward long-term disease modification and improved functional outcomes. As clinical development progresses, the Dravet Syndrome Treatment Market is positioned to become a leading example of how precision medicine can transform rare neurological disease management from supportive care into targeted therapeutic intervention. Dravet Syndrome Treatment Market Report Coverage Table Report Attribute Details Forecast Period 2026 – 2032 Market Size Value in 2025 USD 470 Million Revenue Forecast in 2032 USD 937 Million Overall Growth Rate CAGR of 10.25% (2026 – 2032) Base Year for Estimation 2025 Historical Data 2019 – 2024 Unit USD Million, CAGR (2026 – 2032) Segmentation By Treatment Type, By Therapy Approach, By Distribution Channel, By End User, By Geography By Treatment Type Antiepileptic Drugs, Cannabidiol-Based Therapies, Fenfluramine-Based Therapies, Stiripentol Therapy, Gene-Targeted Therapies, Adjunctive Therapies By Therapy Approach Pharmacological Treatment, Non-Pharmacological Treatment By Distribution Channel Hospital Pharmacies, Retail Pharmacies, Online Pharmacies By End User Hospitals & Specialty Clinics, Diagnostic Laboratories, Research Institutes, Pharmaceutical Companies By Region North America, Europe, Asia Pacific, Latin America, Middle East & Africa Country Scope U.S., Canada, UK, Germany, France, Italy, Spain, Japan, Australia, South Korea, China, India, Brazil, Mexico, Argentina, Saudi Arabia, UAE, South Africa Market Drivers Improving SCN1A genetic diagnosis, adoption of syndrome-specific medicines, development of gene-targeted therapies, expansion of specialty epilepsy centers, coordinated pharmacy access, and increasing rare-disease research activity Customization Option Available upon request Frequently Asked Question About This Report Q1. What are the main treatment approaches used for managing the condition? A1. Management primarily involves pharmacological treatment, including maintenance antiseizure medicines, syndrome-specific therapies, and rescue medications. Non-pharmacological approaches such as ketogenic dietary therapy, vagus nerve stimulation, rehabilitation, and seizure-trigger management are also used for selected patients whose symptoms remain difficult to control. Q2. Which treatment category currently represents the largest market segment? A2. Antiepileptic drugs represent the leading segment, accounting for approximately 38% share and USD 178.6 million in 2025. Their leadership is supported by long-term use of medicines such as valproate and clobazam, which remain foundational therapies and are often combined with newer syndrome-specific treatments. Q3. Why are gene-targeted therapies considered a major future growth opportunity? A3. Gene-targeted therapies are considered a high-growth opportunity because they aim to address the underlying SCN1A-related disease mechanism rather than only controlling seizures. This segment accounted for approximately 7% share and USD 32.9 million in 2025 and is projected to grow at a CAGR of 25.0% during 2026–2032, supported by investigational therapies such as antisense oligonucleotides and gene-regulation approaches. Q4. Which healthcare settings play the most important role in patient management? A4. Hospitals and specialty clinics represent the leading end-user segment, accounting for approximately 62% share and USD 291.4 million in 2025. These facilities provide genetic diagnosis, treatment selection, seizure monitoring, emergency management, multidisciplinary care, and access to clinical trials evaluating emerging therapies. Q5. Which region currently dominates the market and what factors support its leadership? A5. North America leads the market with approximately 45% share and USD 211.5 million in 2025. Its position is supported by advanced epilepsy centers, broader genetic testing availability, access to approved therapies such as Epidiolex, Fintepla, and Diacomit, specialty pharmacy infrastructure, and active development of precision therapies. Q6. How is the treatment landscape expected to evolve in the coming years? A6. The treatment landscape is expected to shift from symptom control toward precision-based disease management. Future growth will be driven by earlier genetic diagnosis, SCN1A-directed therapies, improved patient identification, personalized treatment strategies, and therapies designed to reduce seizure burden while improving long-term developmental and functional outcomes. Sources: Government and Clinical Sources NINDS — Dravet Syndrome NCBI GeneReviews — SCN1A Seizure Disorders NIH/PubMed — U.S. Dravet Syndrome Incidence NIH/PubMed — Dravet Syndrome Mortality NIH/PubMed — SCN1A Dravet Syndrome Definition FDA — Epidiolex Approval FDA — Epidiolex Prescribing Information FDA — Fintepla Approval DailyMed — Fintepla Prescribing Information FDA — Diacomit Approval DailyMed — Diacomit Prescribing Information EMA — Epidyolex EMA — Fintepla EMA — Diacomit ClinicalTrials.gov — Zorevunersen Phase III EMPEROR Study ClinicalTrials.gov — Zorevunersen Phase I/II Study ClinicalTrials.gov — ETX101 ENDEAVOR Study ClinicalTrials.gov — ETX101 WAYFINDER Study Company Sources UCB — Fintepla UCB — Fintepla Clinical Studies Jazz Pharmaceuticals — Epidiolex Prescribing Information Jazz Pharmaceuticals — 2025 Financial Results Biocodex — Rare Epilepsy and Diacomit Biocodex — Diacomit Biogen and Stoke Therapeutics — Zorevunersen Phase III Study Stoke Therapeutics — EMPEROR Phase III Enrollment Encoded Therapeutics — ETX101 Encoded Therapeutics — ETX101 Clinical Studies Encoded Therapeutics — ETX101 Pivotal Study Table of Contents - Global Dravet Syndrome Treatment Market Report (2026–2032) Executive Summary Market Overview Market Attractiveness by Treatment Type, Therapy Approach, Distribution Channel, End User, and Region Strategic Insights from Key Executives (CXO Perspective) Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Summary of Market Segmentation by Treatment Type, Therapy Approach, Distribution Channel, End User, and Region Market Share Analysis Leading Players by Revenue and Market Share Market Share Analysis by Treatment Type, Therapy Approach, Distribution Channel, and End User Investment Opportunities in the Dravet Syndrome Treatment Market Key Developments and Innovations Mergers, Acquisitions, and Strategic Partnerships High-Growth Segments for Investment Opportunities in Antiepileptic Drugs, Cannabidiol-Based Therapies, Fenfluramine-Based Therapies, Stiripentol Therapy, Gene-Targeted Therapies, and Adjunctive Therapies Market Introduction Definition and Scope of the Study Market Structure and Key Findings Overview of Top Investment Pockets Strategic Importance of Genetic Diagnosis, Syndrome-Specific Therapies, and Lifelong Dravet Syndrome Management Research Methodology Research Process Overview Primary and Secondary Research Approaches Market Size Estimation and Forecasting Techniques Data Triangulation and Segment-Level Forecasting Approach Market Dynamics Key Market Drivers Challenges and Restraints Impacting Growth Emerging Opportunities for Stakeholders Impact of Genetic Diagnosis, Rare-Epilepsy Care Pathways, and Treatment Access Factors Role of Syndrome-Specific Medicines, Genetic Testing, Specialty Pharmacies, Ketogenic Dietary Programs, and Neuromodulation in Market Expansion SCN1A-Targeted Development, Disease-Modifying Therapy Research, Multidisciplinary Care, and Long-Term Treatment Management Trends Global Dravet Syndrome Treatment Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Treatment Type: Antiepileptic Drugs Cannabidiol-Based Therapies Fenfluramine-Based Therapies Stiripentol Therapy Gene-Targeted Therapies Adjunctive Therapies Market Analysis by Therapy Approach: Pharmacological Treatment Non-Pharmacological Treatment Market Analysis by Distribution Channel: Hospital Pharmacies Retail Pharmacies Online Pharmacies Market Analysis by End User: Hospitals & Specialty Clinics Diagnostic Laboratories Research Institutes Pharmaceutical Companies Market Analysis by Region: North America Europe Asia Pacific Latin America Middle East & Africa Regional Market Analysis North America Dravet Syndrome Treatment Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Treatment Type, Therapy Approach, Distribution Channel, and End User Country-Level Breakdown: United States Canada Europe Dravet Syndrome Treatment Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Treatment Type, Therapy Approach, Distribution Channel, and End User Country-Level Breakdown: Germany United Kingdom France Italy Spain Rest of Europe Asia Pacific Dravet Syndrome Treatment Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Treatment Type, Therapy Approach, Distribution Channel, and End User Country-Level Breakdown: Japan Australia South Korea China India Rest of Asia Pacific Latin America Dravet Syndrome Treatment Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Treatment Type, Therapy Approach, Distribution Channel, and End User Country-Level Breakdown: Brazil Mexico Argentina Rest of Latin America Middle East & Africa Dravet Syndrome Treatment Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Treatment Type, Therapy Approach, Distribution Channel, and End User Country-Level Breakdown: Saudi Arabia United Arab Emirates South Africa Rest of Middle East & Africa Competitive Intelligence and Benchmarking Leading Key Players: UCB Jazz Pharmaceuticals Biocodex Stoke Therapeutics Biogen Encoded Therapeutics Ovid Therapeutics Xenon Pharmaceuticals SK Biopharmaceuticals Marinus Pharmaceuticals Competitive Landscape and Strategic Insights Benchmarking Based on Syndrome-Specific Treatment Portfolio, Genetic-Medicine Development, Clinical Evidence, Specialty Pharmacy Infrastructure, Rare-Epilepsy Expertise, and Regional Presence Pipeline and Clinical Development Capability Analysis Genetic Diagnosis and SCN1A-Targeted Therapy Positioning Antiepileptic, Cannabidiol-Based, Fenfluramine-Based, and Stiripentol Therapy Competitiveness Specialty Pharmacy, Patient Access, Genetic Testing, and Multidisciplinary Care Strategy Analysis Appendix Abbreviations and Terminologies Used in the Report References and Sources List of Tables Market Size by Treatment Type, Therapy Approach, Distribution Channel, End User, and Region (2026–2032) Regional Market Breakdown by Segment Type (2026–2032) Competitive Benchmarking of Leading Vendors Genetic Diagnosis, Clinical Development, and Treatment Access Analysis Therapy Adoption Trends Across Antiepileptic Drugs, Cannabidiol-Based Therapies, Fenfluramine-Based Therapies, Stiripentol Therapy, Gene-Targeted Therapies, and Adjunctive Therapies List of Figures Market Drivers, Challenges, Opportunities, and Restraints Regional Market Snapshot Competitive Landscape by Market Share Growth Strategies Adopted by Key Players Market Share by Treatment Type, Therapy Approach, Distribution Channel, and End User (2025 vs. 2032) Global Dravet Syndrome Treatment Ecosystem and Value Chain Analysis